Rui Liu1, David M Umbach2, Shyamal D Peddada2, Zongli Xu2, Alexander I Tröster2, Xuemei Huang2, Honglei Chen2. 1. From the Epidemiology Branch (R.L., Z.X., H.C.) and Biostatistics and Computational Biology Branch (D.M.U., S.D.P.) of the National Institute of Environmental Health Sciences, Research Triangle Park, NC; Barrow Neurological Institute (A.I.T.), Phoenix, AZ; Department of Neurology (X.H.), Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA. liur2@niehs.nih.gov. 2. From the Epidemiology Branch (R.L., Z.X., H.C.) and Biostatistics and Computational Biology Branch (D.M.U., S.D.P.) of the National Institute of Environmental Health Sciences, Research Triangle Park, NC; Barrow Neurological Institute (A.I.T.), Phoenix, AZ; Department of Neurology (X.H.), Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA.
Abstract
OBJECTIVE: To examine potential sex differences in nonmotor symptoms (NMS) among drug-naive patients with Parkinson disease (PD), and to identify NMS that can best differentiate patients with early PD from controls. METHODS: Our cross-sectional analysis included 414 newly diagnosed, untreated patients with PD (269 men and 145 women) and 188 healthy controls (121 men and 67 women) in the Parkinson's Progression Markers Initiative Study. NMS were measured using well-validated instruments covering sleep, olfactory, neurobehavioral, autonomic, and neuropsychological domains. RESULTS: Male and female patients with PD were fairly comparable on motor presentations but differed on several nonmotor features. Male patients with PD had significantly more pronounced deficits in olfaction (p = 0.02) and in certain cognitive measurements (all p < 0.01) than female patients, whereas female cases experienced higher trait anxiety (p = 0.02). Multiple stepwise logistic regression analysis showed that the combination of NMS measures-University of Pennsylvania Smell Identification Test (UPSIT), Montreal Cognitive Assessment (MoCA), Scales for Outcomes in Parkinson's Disease-Autonomic (SCOPA-AUT), and state anxiety from the State-Trait Anxiety Inventory-effectively differentiated patients with PD from controls with an area under the receiver operating characteristic curve (AUC) of 0.913 (95% confidence interval [CI]: 0.89-0.94). UPSIT, MoCA, and SCOPA-AUT were the most predictive NMS measurements in men (AUC = 0.919; 95% CI: 0.89-0.95) as compared to UPSIT, MoCA, and REM Sleep Behavior Disorder Screening Questionnaire in women (AUC = 0.903; 95% CI: 0.86-0.95). CONCLUSIONS: Our analysis revealed notable sex differences in several nonmotor features of patients with de novo PD. Furthermore, we found a parsimonious NMS combination that could effectively differentiate de novo cases from healthy controls.
OBJECTIVE: To examine potential sex differences in nonmotor symptoms (NMS) among drug-naive patients with Parkinson disease (PD), and to identify NMS that can best differentiate patients with early PD from controls. METHODS: Our cross-sectional analysis included 414 newly diagnosed, untreated patients with PD (269 men and 145 women) and 188 healthy controls (121 men and 67 women) in the Parkinson's Progression Markers Initiative Study. NMS were measured using well-validated instruments covering sleep, olfactory, neurobehavioral, autonomic, and neuropsychological domains. RESULTS: Male and female patients with PD were fairly comparable on motor presentations but differed on several nonmotor features. Male patients with PD had significantly more pronounced deficits in olfaction (p = 0.02) and in certain cognitive measurements (all p < 0.01) than female patients, whereas female cases experienced higher trait anxiety (p = 0.02). Multiple stepwise logistic regression analysis showed that the combination of NMS measures-University of Pennsylvania Smell Identification Test (UPSIT), Montreal Cognitive Assessment (MoCA), Scales for Outcomes in Parkinson's Disease-Autonomic (SCOPA-AUT), and state anxiety from the State-Trait Anxiety Inventory-effectively differentiated patients with PD from controls with an area under the receiver operating characteristic curve (AUC) of 0.913 (95% confidence interval [CI]: 0.89-0.94). UPSIT, MoCA, and SCOPA-AUT were the most predictive NMS measurements in men (AUC = 0.919; 95% CI: 0.89-0.95) as compared to UPSIT, MoCA, and REM Sleep Behavior Disorder Screening Questionnaire in women (AUC = 0.903; 95% CI: 0.86-0.95). CONCLUSIONS: Our analysis revealed notable sex differences in several nonmotor features of patients with de novo PD. Furthermore, we found a parsimonious NMS combination that could effectively differentiate de novo cases from healthy controls.
Authors: Brit Mollenhauer; Ellen Trautmann; Friederike Sixel-Döring; Tamara Wicke; Jens Ebentheuer; Martina Schaumburg; Elisabeth Lang; Niels K Focke; Kishore R Kumar; Katja Lohmann; Christine Klein; Michael G Schlossmacher; Ralf Kohnen; Tim Friede; Claudia Trenkwalder Journal: Neurology Date: 2013-08-30 Impact factor: 9.910
Authors: Marina Picillo; Marianna Amboni; Roberto Erro; Katia Longo; Carmine Vitale; Marcello Moccia; Angela Pierro; Gabriella Santangelo; Anna De Rosa; Giuseppe De Michele; Lucio Santoro; Giuseppe Orefice; Paolo Barone; Maria Teresa Pellecchia Journal: J Neurol Date: 2013-08-30 Impact factor: 4.849
Authors: Konrad Szewczyk-Krolikowski; Paul Tomlinson; Kannan Nithi; Richard Wade-Martins; Kevin Talbot; Yoav Ben-Shlomo; Michele T M Hu Journal: Parkinsonism Relat Disord Date: 2013-10-12 Impact factor: 4.891
Authors: Honglei Chen; Edward A Burton; G Webster Ross; Xuemei Huang; Rodolfo Savica; Robert D Abbott; Alberto Ascherio; John N Caviness; Xiang Gao; Kimberly A Gray; Jau-Shyong Hong; Freya Kamel; Danna Jennings; Annette Kirshner; Cindy Lawler; Rui Liu; Gary W Miller; Robert Nussbaum; Shyamal D Peddada; Amy Comstock Rick; Beate Ritz; Andrew D Siderowf; Caroline M Tanner; Alexander I Tröster; Jing Zhang Journal: Environ Health Perspect Date: 2013-08-09 Impact factor: 9.031
Authors: P Solla; C Masala; A Liscia; R Piras; T Ercoli; L Fadda; T Hummel; A Haenher; G Defazio Journal: J Neurol Date: 2019-09-25 Impact factor: 4.849
Authors: Matthew Swan; Nancy Doan; Robert A Ortega; Matthew Barrett; William Nichols; Laurie Ozelius; Jeannie Soto-Valencia; Sarah Boschung; Andres Deik; Harini Sarva; Jose Cabassa; Brooke Johannes; Deborah Raymond; Karen Marder; Nir Giladi; Joan Miravite; William Severt; Rivka Sachdev; Vicki Shanker; Susan Bressman; Rachel Saunders-Pullman Journal: J Neurol Sci Date: 2016-08-30 Impact factor: 3.181
Authors: Brenna Cholerton; Catherine O Johnson; Brian Fish; Joseph F Quinn; Kathryn A Chung; Amie L Peterson-Hiller; Liana S Rosenthal; Ted M Dawson; Marilyn S Albert; Shu-Ching Hu; Ignacio F Mata; James B Leverenz; Kathleen L Poston; Thomas J Montine; Cyrus P Zabetian; Karen L Edwards Journal: Parkinsonism Relat Disord Date: 2018-02-09 Impact factor: 4.891